Abstract
Progestin-primed ovarian stimulation (PPOS) protocol has recently been demonstrated to be an novel regimen for preventing premature LH surges during controlled ovarian hyperstimulation (COH) in combination with frozen-thawed embryo transfer (FET). Our prospective controlled study was to explore the effect of human chorionic gonadotropin (hCG) contained in human menopausal gonadotropin (hMG) on the clinical outcomes in normalovulatory women undergoing COH with PPOS. A total of 180 patients were allocated into three groups according to the gonadotropin (Gn) used: group A (human menopausal gonadotropin, hMG-A), group B (hMG-B) or group C (follicle stimulating hormone, FSH). The primary outcome measured was the number of oocytes retrieved. The number of oocytes retrieved in group A B C was 10.72±5.78 11.33±5.19and13.38±8.97, respectively, with no statistic significance (p>0.05). Other embryological indicators were also similar (p>0.05). The concentration of serum and urinary β-hCG on the trigger day in group A and B were not associated with embryo results (p>0.05). There was no significant differences in the clinical pregnancy rate (41.67% vs. 51.56% vs. 39.51%, p>0.05) and implantation rate (31.58%vs. 34.75%vs.25.33%) after FET among the three groups. Thus the clinical characteristics were not affected by the hCG contained in hMG in normalovulatory women treated with PPOS.
Highlights
Gonadotropin (Gn) has been used to induce the development of multiple follicles and increase the efficiency of ovarian stimulation in women with infertility since the 1960s
Progestin-primed ovarian stimulation (PPOS) protocol has recently been demonstrated to be an novel regimen for preventing premature luteinizing hormone (LH) surges during controlled ovarian hyperstimulation (COH) in combination with frozen-thawed embryo transfer (FET)
The other parameters were similar among the 3 groups. This is the first prospective controlled cohort study investigating the effect of human chorionic gonadotropin (hCG) in human menopausal gonadotropin (hMG) on the clinical outcomes of normal ovulatory women undergoing in vitro fertilization (IVF)/ intracytoplasmic sperm injection (ICSI) treatments in the PPOS protocol
Summary
Gonadotropin (Gn) has been used to induce the development of multiple follicles and increase the efficiency of ovarian stimulation in women with infertility since the 1960s. The human menopausal gonadotropin (hMG) with both follicle stimulating hormone (FSH) and luteinizing hormone (LH) activity was used. Since some studies suggested that hCG components in hMG were detrimental to follicle growth and oocyte www.impactjournals.com/oncotarget maturation, there was once a gradual shift from hMG to recombinant human FSH (r-FSH) [1, 7]. Some researcher observed that hCG alone was able to induce follicular growth instead of FSH [8], a beneficial effect of adding low-dose hCG to FSH was reported in patients with hypogonadotropic hypogonadism [9], polycystic ovarian syndrome [10] or poor ovarian response [11]. The administration of exogenous LHactivity components was still controversial in the GnRH agonist or antagonist protocol
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
